FDA Hikes Fees for Your Pet's Generic Meds in 2026
Published Date: 7/30/2025
Notice
Summary
The FDA is setting the fees and payment rules for companies making generic animal drugs in fiscal year 2026. If you create or sponsor these generic animal medicines, expect some updated costs and deadlines to keep your products moving. These changes help the FDA keep things running smoothly and on time for safer, affordable animal meds.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
FY2026 Generic Animal Drug User Fees
If you make or sponsor generic animal drugs, the FDA is setting new user fee rates and payment procedures for fiscal year 2026. The fees apply to certain abbreviated new animal drug applications, certain generic new animal drug products, sponsors of those applications and investigational submissions for generic new animal drugs (JINADs), and related submissions.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20503, Determination That Oxandrin (Oxandrolone) Tablets, 2.5 Milligrams and 10 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness; Correction
The FDA fixed a previous announcement about Oxandrin tablets (2.5 mg and 10 mg) being pulled from the market due to safety or effectiveness concerns. This update confirms that not only the original drug but also several generic versions were withdrawn and removed from the official drug list. Patients, doctors, and drug makers should note these changes, which affect availability and prescribing options immediately.
Previous / Next Documents
Previous: 2025-14408, 2030 Census Redistricting Data Program, Commencement of Phase 1: The Block Boundary Suggestion Project
The 2030 Census is kicking off Phase 1 of its Redistricting Data Program, where states can suggest new boundaries for small areas used in drawing voting districts. This is a chance for states to help shape the map by pointing out roads or legal lines that should mark these boundaries. Participation is voluntary, and this early input helps make sure the 2030 Census data fits states’ needs for fair representation.
Next: 2025-14410, Outsourcing Facility Fee Rates for Fiscal Year 2026
If you run a drug-compounding outsourcing facility, the FDA just set the fees for fiscal year 2026. Small businesses will pay $6,829, while bigger ones owe $20,726, plus $20,486 for any reinspections. These fees help keep drug safety in check, so get ready to pay on time and keep your facility in tip-top shape!